WHAT IS CLAIMED IS:

1. A method for reducing the frequency of urination, comprising:

administering to a subject in need thereof a pharmaceutical composition comprising:

one or more analgesic agents; and

one or more additional active ingredients selected from the group consisting of α-blockers and 5α-reductase inhibitors.

2. The method of Claim 1, wherein said one or more analgesic agents and said one or more additional active ingredients are formulated for immediate release. 3. The method of Claim 1, wherein said one or more analgesic agents and said one or more additional active ingredients are formulated for delayed release.

4. The method of Claim 1, wherein said one or more analgesic agents and said one or more additional active ingredients are formulated for extended release.

5. The method of Claim 4, wherein said one or more analgesic agents are administered

in an amount of 50-400 mg per agent, wherein said one or more analgesic agents are selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin, nabumetone, and acetaminophen, and wherein said pharmaceutical composition is formulated for extended-release such that said one or more analgesic agents and said one or more additional active ingredients are released continuously over a period of 5-24 hours.

6. The method of Claim 5, wherein said one or more additional active ingredients comprise tamsulosin.

7. The method of Claim 5, wherein said one or more additional active ingredients comprise finasteride.

8. The method of Claim 5, wherein said one or more additional active ingredients comprise tamsulosin and finasteride.

9. The method of Claim 4, wherein said one or more analgesic agents are administered

in an amount of 50-400 mg per agent, wherein said one or more analgesic agents are selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin, nabumetone, and acetaminophen, and wherein said pharmaceutical composition is formulated for extended release, characterized by a two-phase release profile in which 20-60% of said one or more analgesic agents are released within two hours of administration and remainder of said one or more analgesic agents are released continuously over a period of 5-24 hours.

10. The method of Claim 9, wherein said one or more additional active ingredients comprise tamsulosin.

11. The method of Claim 9, wherein said one or more additional active ingredients comprise finasteride.

12. The method of Claim 9, wherein said one or more additional active ingredients comprise tamsulosin and finasteride.

13. The method of Claim 1, wherein said one or more analgesic agents are formulated for extended release and said one or more additional active ingredients are formulated for immediate release.

14. The method of Claim 13, wherein said one or more analgesic agents are administered

in an amount of 50-400 mg per agent, wherein said one or more analgesic agents are selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin, nabumetone, and acetaminophen, and wherein said one or more analgesic agents are formulated for extended-release such that said one or more analgesic agents are released continuously over a period of 5-24 hours.

15. The method of Claim 14, wherein said one or more additional active ingredients comprise tamsulosin.

16. The method of Claim 14, wherein said one or more additional active ingredients comprise finasteride.

17. The method of Claim 14, wherein said one or more additional active ingredients comprise tamsulosin and finasteride.

18. The method of Claim 13, wherein said one or more analgesic agents are administered

in an amount of 50-400 mg per agent, wherein said one or more analgesic agents are selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin, nabumetone, and acetaminophen, and wherein said one or more analgesic agents are formulated for extended release, characterized by a two-phase release profile in which 20-60% of said one or more analgesic agents are released within two hours of administration and remainder of said one or more analgesic agents are released continuously over a period of 5-24 hours.

19. The method of Claim 18, wherein said one or more additional active ingredients comprise tamsulosin.

20. The method of Claim 18, wherein said one or more additional active ingredients comprise finasteride.

21. The method of Claim 18, wherein said one or more additional active ingredients comprise tamsulosin and finasteride.

22. The method of Claim 1, wherein said pharmaceutical composition further comprises an antimuscarinic agent.

23. The method of Claim 1, wherein said pharmaceutical composition further comprises an antidiuretic agent.

24. The method of Claim 1, wherein said pharmaceutical composition further comprises a spasmolytic.

25. The method of Claim 1, further comprising the step of administering an effective amount of a diuretic prior to the administration of said pharmaceutical composition, wherein said diuretic is administered 7 or 8 hours prior to bedtime.

26. The method of Claim 1, wherein said subject is a mammal.

27. A pharmaceutical composition for reducing frequency of urination, comprising:

one or more analgesic agents;

one or more α-blockers, and

a pharmaceutically acceptable carrier'

wherein said one or more analgesic agents are formulated for extended release and wherein said one or more α-blockers are formulated for immediate release.

28. The pharmaceutical composition of Claim 27, comprising one or more analgesic agents in an amount of 50-400 mg per agent, wherein said one or more analgesic agents are selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin, nabumetone, and acetaminophen, and wherein said one or more analgesic agents are formulated for extended-release such that said one or more analgesic agents are released continuously over a period of 5-24 hours.

29. The pharmaceutical composition of Claim 28, wherein said one or more analgesic agents comprise acetaminophen and wherein said one or more α-blockers comprise tamsulosin.

30. The pharmaceutical composition of Claim 27, comprising one or more analgesic agents in an amount of 50-400 mg per agent, wherein said one or more analgesic agents are selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin, nabumetone, and acetaminophen, and wherein said pharmaceutical composition is formulated for extended release, characterized by a two-phase release profile

in which 20-60% of said one or more analgesic agents are released within two hours of administration and remainder of said one or more analgesic agents are released continuously over a period of 5-24 hours.

31. The pharmaceutical composition of Claim 30, wherein said one or more analgesic agents comprise acetaminophen and wherein said one or more α-blockers comprise tamsulosin.

32. A pharmaceutical composition for reducing frequency of urination, comprising:

one or more analgesic agents;

one or more 5α-reductase inhibitors, and

a pharmaceutically acceptable carrier

wherein said one or more analgesic agents are formulated for extended release and wherein said one or more 5α-reductase inhibitors are formulated for immediate release.

33. The pharmaceutical composition of Claim 32, comprising one or more analgesic agents in an amount of 50-400 mg per agent, wherein said one or more analgesic agents are selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin, nabumetone, and acetaminophen, and wherein said one or more analgesic agents are formulated for extended-release such that said one or more analgesic agents are released continuously over a period of 5-24 hours.

34. The pharmaceutical composition of Claim 33, wherein said one or more analgesic agents comprise acetaminophen and wherein said one or more 5α-reductase inhibitors comprise finasteride.

35. The pharmaceutical composition of Claim 32, comprising one or more analgesic agents in an amount of 50-400 mg per agent, wherein said one or more analgesic agents are selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin, nabumetone, and acetaminophen, and wherein said pharmaceutical composition is formulated for extended release, characterized by a two-phase release profile in which 20-60% of said one or more analgesic agents are released within two hours of administration and remainder of said one or more analgesic agents are released continuously over a period of 5-24 hours.

36. The pharmaceutical composition of Claim 35, wherein said one or more analgesic agents comprise acetaminophen and wherein said one or more 5α-reductase inhibitors comprise finasteride.

WHAT IS CLAIM IS:

1. Use of a pharmaceutical composition comprising:

one or more analgesic agents; and

one or more additional active ingredients selected from the group consisting of α-blockers and 5α-reductase inhibitors, wherein said one or more analgesic agents comprise acetaminophen, in the manufacture of a medicament for treating nocturia.

2. The use of Claim 1, wherein said one or more analgesic agents and said one or more additional active ingredients are formulated for immediate release.

3. The use of Claim 1, wherein said one or more analgesic agents and said one or more additional active ingredients are formulated for delayed release.

4. The use of Claim 1, wherein said one or more analgesic agents and said one or more additional active ingredients are formulated for extended release.

5. The use of Claim 4, wherein said one or more analgesic agents are administered in an amount of 50-2000 mg per agent, wherein said pharmaceutical composition is formulated for extended-release such that said one or more analgesic agents and said one or more additional active ingredients are released continuously over a period of 5-24 hours.

6. The use of Claim 5, wherein said one or more additional active ingredients comprise tamsulosin.

7. The use of Claim 5, wherein said one or more additional active ingredients comprise finasteride.

8. The use of Claim 5, wherein said one or more additional active ingredients comprise tamsulosin and finasteride.

9. The use of Claim 4, wherein said one or more analgesic agents are administered in an amount of 50-2000 mg per agent, and wherein said pharmaceutical composition is formulated for extended release, characterized by a two-phase release profile in which 20-60% of said one or more analgesic agents are released within two hours of administration and remainder of said one or more analgesic agents are released continuously over a period of 5-24 hours.

10. The use of Claim 9, wherein said one or more additional active ingredients comprise tamsulosin.

11. The use of Claim 9, wherein said one or more additional active ingredients comprise finasteride.

12. The use of Claim 9, wherein said one or more additional active ingredients comprise tamsulosin and finasteride.

13. The use of Claim 1, wherein said one or more analgesic agents are formulated for extended release and said one or more additional active ingredients are formulated for immediate release.

14. The use of Claim 13, wherein said one or more analgesic agents are administered in an amount of 50-2000 mg per agent, wherein said one or more analgesic agents are formulated for extended-release such that said one or more analgesic agents are released continuously over a period of 5-24 hours.

15. The use of Claim 14, wherein said one or more additional active ingredients comprise tamsulosin.

16. The use of Claim 14, wherein said one or more additional active ingredients comprise finasteride.

17. The use of Claim 14, wherein said one or more additional active ingredients comprise tamsulosin and finasteride.

18. The use of Claim 13, wherein said one or more analgesic agents are administered in an amount of 50-2000 mg per agent, wherein said pharmaceutical composition additionally comprises one or more analgesic agents selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin, and nabumetone, and wherein said one or more analgesic agents are formulated for extended release, characterized by a two-phase release profile in which 20-60% of said one or more analgesic agents are released within two hours of administration and remainder of said one or more analgesic agents are released continuously over a period of 5-24 hours.

19. The use of Claim 18, wherein said one or more additional active ingredients comprise tamsulosin.

20. The use of Claim 18, wherein said one or more additional active ingredients comprise finasteride.

21. The use of Claim 18, wherein said one or more additional active ingredients comprise tamsulosin and finasteride.

22. The use of Claim 1, wherein said pharmaceutical composition further comprises an antimuscarinic agent.

23. The use of Claim 1, wherein said pharmaceutical composition further comprises an antidiuretic agent.

24. The use of Claim 1, wherein said pharmaceutical composition further comprises a spasmolytic.

25. The use of Claim 1, further comprising the step of administering an effective amount of a diuretic prior to the administration of said pharmaceutical composition, wherein said diuretic is administered 7 or 8 hours prior to bedtime.

26. The use of Claim 1, wherein said subject is a mammal.

27. A pharmaceutical composition for reducing frequency of urination, comprising:

one or more analgesic agents;

one or more α-blockers, and

a pharmaceutically acceptable carrier'

wherein said one or more analgesic agents comprise acetaminophen;

wherein said one or more analgesic agents are formulated for extended release and wherein said one or more α-blockers are formulated for immediate release.

28. The pharmaceutical composition of Claim 27, comprising one or more analgesic agents in an amount of 50-400 mg per agent, wherein said one or more analgesic agents are selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin, nabumetone, and acetaminophen, and wherein said one or more analgesic agents are formulated for extended-release such that said one or more analgesic agents are released continuously over a period of 5-24 hours.

29. The pharmaceutical composition of Claim 28, wherein said one or more analgesic agents comprise acetaminophen and wherein said one or more α-blockers comprise tamsulosin.

30. The pharmaceutical composition of Claim 27, comprising one or more analgesic agents in an amount of 50-400 mg per agent, wherein said one or more analgesic agents are selected from the group consisting of aspirin, ibuprofen, naproxen, naproxen sodium, indomethacin, nabumetone, and acetaminophen, and wherein said pharmaceutical composition is formulated for extended release, characterized by a two-phase release profile in which 20-60% of said one or more analgesic agents are released within two hours of administration and remainder of said one or more analgesic agents are released continuously over a period of 5-24 hours.

31. The pharmaceutical composition of Claim 30, wherein said one or more analgesic agents comprise acetaminophen and wherein said one or more α-blockers comprise tamsulosin.

32. The use of the pharmaceutical composition of Claim 1, wherein said one or more analgesic agents and said one or more additional active ingredients are formulated for immediate release, extended release, delayed release or combinations thereof.

33. The use of the pharmaceutical composition of Claim 1, wherein said pharmaceutical composition is in a liquid or solid formulation.

34. The pharmaceutical composition of Claim 27, wherein said pharmaceutical composition is in a liquid or solid formulation.